Atai Beckley Inc.

NASDAQ:ATAI

Biotechnology

Healthcare
$7.35 -1.35%

-$0.06 today

Market cap
$2.72B
Beta
1.60
P/E (TTM)
-1.4
EPS (TTM)
-$2.93
52W Low $2.00High $6.75

Volume 0.00M

Average 5.68M

ATAI Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Atai Beckley Inc.NASDAQ: ATAI

Net Change in Cash · Q2 FY2026 · quarter ended Jun 2026

Net change in cash growth accelerates

Q2 FY2026 net change in cash of $125.71M rose 3341.1% year over year, ahead of the +287.1% change in trailing-twelve-month net change in cash.

Context

  • Net change in cash amounted to 1413.4% of revenue in FY2025, down 4277.8 pp from a year earlier.
  • Net change in cash increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +3341.1% holds above the trailing-twelve-month pace of +287.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$125.71M+397.9% QoQ
Last fiscal yearDec 2025
$57.8M+429.7% YoY
LTMJun 2026
$106.87M+287.1% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3341.1%——
1 year+429.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
57.8M USD
Year-over-year change
+429.7%
4-year CAGR
-31.7%

Net Change in Cash vs competitors

How ATAI compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +287.1% is the 2nd highest of 11, against a peer median of +26.9%.
  • Net change in cash amounts to 2389.2% of revenue for ATAI, versus a peer median of 99.7%.
ATAI Competitors
Net Change in Cash for ATAI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ATAIAtai Beckley Inc.LTM Jun 2026$106.87M USD+287.1%—2389.2%
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$97.25M USD+132.3%+53.6%5107.6%
INBXInhibrx Biosciences, Inc.LTM Mar 2026$54.86M USD+52.6%—4220.2%
IMTXImmatics N.V.LTM Mar 2026€51.59M EUR-57.3%+106.7%138.3%
ELVNEnliven Therapeutics, Inc.LTM Sep 2026$49.94M USD+4624.2%-9.8%—
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$23.22M USD-159.0%-49.3%10.7%
NKTRNektar TherapeuticsLTM Jun 2026$15.21M USD+1.2%—27.9%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$14.93M USD-90.3%+126.2%—
SANASana Biotechnology, Inc.LTM Mar 2026$12.33M USD-84.7%-9.5%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$7.06M USD+200.5%-55.8%—
RLAYRelay Therapeutics, Inc.LTM Jun 2026$6.33M USD+130.7%-31.6%61.1%
Peer median (excluding ATAI) —+26.9%-9.7%99.7%

Competitors are the stored peer set for ATAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(174.24M)(157.42M)(43.9M)(150.05M)(660.05M)
Depreciation & Amortization47K168K319K473K1.01M
Deferred Income Tax39.14M5.07M000
Stock-Based Compensation63.36M42.38M32.98M25.49M0
Change in Working Capital(7.6M)(3.34M)7.47M(9.2M)(6.48M)
Accounts Receivables00000
Inventory00000
Accounts Payables2.3M(3.03M)2.14M(1.87M)(1.7M)
Other Working Capital(9.9M)(301K)5.33M(7.33M)(4.78M)
Other Non-Cash Items16.06M8.67M(80.99M)50.85M562.84M
Operating Cash Flow(63.25M)(104.47M)(84.12M)(82.44M)(102.68M)
Capital Expenditures(1.13M)(1.02M)(590K)(95K)(901K)
Acquisitions (Net)(52.94M)0(443K)359K4.64M
Purchases of Investments(23.66M)(309.66M)(186.22M)(15M)(98.95M)
Sales of Investments(955K)226.83M139.47M82.01M9.05M
Other Investing Activities(2.6M)(3.25M)(5.84M)(8.1M)(13M)
Investing Cash Flow(81.28M)(86.85M)(53.3M)59.17M(109.13M)
Debt Repayment1.59M15M05M7.71M
Common Stock Issued409.88M00535K283.43M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.42M5.19M(8.36M)(161K)(21.66M)
Financing Cash Flow409.86M20.79M(8.36M)5.37M269.48M
Effect of Forex Changes(320K)(1.12M)189K362K116K
Net Change in Cash265.02M(171.65M)(145.58M)(17.53M)57.8M
Free Cash Flow(64.37M)(105.49M)(84.71M)(82.53M)(103.58M)

Atai Beckley Inc.

NASDAQ:ATAI

Intrinsic Alpha fair value

Locked

Current Price

$7.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.